IL1R1
Interleukin-1 receptor type 1
As of the edition of 20 October 2026, IL1R1 (interleukin-1 receptor type 1, UniProt P14778) has 3 drugs tested at it and 3 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P14778
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 5
- Disease areas
- Immune system; Skin and connective tissue; Heart and blood vessels; Bones, joints and muscles; Infections; Lungs and airways; Cancer; Nutrition and metabolism
- Registered trials of its drugs
- 147
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Anakinra | Marketed | Phase 4 | Ends 2027 |
| AMG-108 | Went quiet | Phase 2 | none listed |
| MEDI-8968 | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
The other 2 companies at IL1R1
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at IL1R1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.